Daewoong Pharmaceutical said Tuesday it hosted the “Nabota Master Class Latin America” (NMC LATAM) on Nov. 6-7 in Seoul and Hwaseong, Gyeonggi Province, inviting leading Argentine medical professionals to Korea.

The event aimed to strengthen Nabota’s (botulinum toxin type A) brand presence in Argentina by sharing its clinical differentiation and treatment expertise, while enhancing brand loyalty and trust. Training sessions focused on Daewoong’s proprietary procedures, NaboLift and NaboGlow, which deliver comprehensive aesthetic benefits.

According to Daewoong, NaboLift involves injecting Nabota into both the skin and muscle layers to improve facial contours and wrinkles, while NaboGlow enhances skin quality. Participants attended lectures by Dr. Park Ji-ho and Dr. Kim Chang-hyun of Cheongdam Oaro Dermatology Clinic, observed live procedures, and toured Korean medical facilities and Daewoong’s Hyangnam plant in Hwaseong, Gyeonggi Province, confirming the company’s global manufacturing quality.

Nabota, marketed as CLODEW through Oxapharma in Argentina, is the first and only Korean botulinum toxin approved in Argentina. Daewoong and Oxapharma are also targeting MZ generation consumers through digital and social media marketing focused on “natural and sophisticated beauty.”

Yoon Jun-soo, head of the Nabota Business Division at Daewoong, said the company will strengthen physician education and MZ marketing to establish Nabota as a premium brand across Latin America.